Featured Publications
Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction
Back J, Nguyen MN, Li L, Lee S, Lee I, Chen F, Gillinov L, Chung YH, Alder KD, Kwon HK, Yu KE, Dussik CM, Hao Z, Flores MJ, Kim Y, Ibe IK, Munger AM, Seo SW, Lee FY. Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction. Bone Research 2021, 9: 43. PMID: 34588427, PMCID: PMC8481290, DOI: 10.1038/s41413-021-00158-w.Peer-Reviewed Original ResearchCancer-induced bone destructionBreast cancer cellsOsteolytic breast cancerBone homeostasisCancer growthCancer cellsBone destructionInflammatory osteolysisBreast cancerBreast cancer-induced bone destructionOsteolytic breast cancer metastasesPromising adjuvant therapyERK1/2 activationMEK1 expressionBreast cancer metastasisMetastatic breast cancer cellsActivation of pERK1/2Inflammatory conversionAdjuvant therapyPathological fracturesHuman pathological specimensBone microenvironmentPathological specimensSkeletal diseasePathway inhibitorAblation, Osteoplasty, Reinforcement, and Internal Fixation for Percutaneous Endoskeletal Reconstruction of Periacetabular and Other Periarticular Osteolytic Metastases.
Toombs C, Conway D, Munger AM, Alder KD, Latich I, Lee FY. Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Percutaneous Endoskeletal Reconstruction of Periacetabular and Other Periarticular Osteolytic Metastases. Instructional Course Lectures 2021, 70: 503-514. PMID: 33438931.Peer-Reviewed Original ResearchConceptsInternal fixationLocal cancer controlBalloon osteoplastySurgical stabilizationCancer controlConventional open surgical proceduresLocal cancer progressionProgressive bone destructionFirst-line treatmentPercutaneous treatment optionsAmbulatory surgery settingProgressive bone lossSurgical reconstructive proceduresEarly clinical resultsImage-guided ablationNew effective therapiesOpen surgical proceduresInvasive surgical interventionOptimal internal fixationOsteolytic metastatic diseasePolymethyl methacrylate cementUncontrolled painMetastatic diseaseBone destructionOsteolytic metastases
2012
Modern Interpretation of Giant Cell Tumor of Bone: Predominantly Osteoclastogenic Stromal Tumor
Kim Y, Nizami S, Goto H, Lee FY. Modern Interpretation of Giant Cell Tumor of Bone: Predominantly Osteoclastogenic Stromal Tumor. Clinics In Orthopedic Surgery 2012, 4: 107-116. PMID: 22662295, PMCID: PMC3360182, DOI: 10.4055/cios.2012.4.2.107.Peer-Reviewed Original ResearchConceptsGiant cell tumorStromal cell-derived factor-1Tumor necrosis factorCell tumorsBone destructionNuclear factor kappa-B ligandCell-derived factor-1Stromal cell tumorsPro-osteoclastogenic cytokinesGCT treatmentAdjuvant therapySurgical excisionStromal tumorsTumor comprisingInflammatory cytokinesChemoattractant proteinNecrosis factorParacrine loopExcessive osteoclastogenesisReceptor activatorOrthopaedic surgeonsOsteoclast precursorsOsteoclastic cellsMesenchymal originTumors
2004
Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis
Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, Kim TW, Winchester RJ, Lee FY. Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis. Clinical Orthopaedics And Related Research® 2004, 426: 103-109. PMID: 15346059, DOI: 10.1097/01.blo.0000141372.54456.80.Peer-Reviewed Original ResearchConceptsGiant cell tumorCell tumorsAdjuvant therapyGiant cellsExogenous receptor activatorSpecific adjuvant therapyExtensive bone destructionTumor culturesLocal adjuvant therapyHigh recurrence rateNovel adjuvant therapyOsteoclastlike giant cellsNovel therapeutic agentsNF-kappaB ligandDose-dependent mannerBone destructionRecurrence rateAggressive tumorsBone resorptionSystemic useReceptor activatorAutocrine loopAutocrine mannerTumorsAutocrine regulation